042520.Kq
The company operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
Business. The company operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare services and equipment industry, primarily generating revenue through the provision of medical equipment, supplies, and distribution services.
The company's capital structure is characterized by a debt-to-equity ratio of 1.28, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 0.69, suggesting limited short-term liquidity. The company's price-to-book ratio is 13.1, which is significantly higher than typical industry norms, reflecting a premium valuation relative to its book value. The company's return on equity is -0.93, and its return on assets is -0.25, both of which are negative and indicate poor profitability and asset utilization.
The company's profitability is weak, with a net loss of 31,341,350,200 KRW and an operating loss of 25,890,557,570 KRW. Its gross profit margin is 57.4%, which is relatively high but insufficient to offset the operating and net losses. The company's free cash flow is negative at -29,177,299,300 KRW, indicating that it is not generating sufficient cash from operations to fund its capital expenditures and other operational needs.
The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification. The company's operations are primarily based in its home market, and there is no indication of substantial international revenue streams. This concentration increases the company's exposure to local economic and regulatory risks.
The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. The company's capital expenditures are negative, suggesting a reduction in investment in long-term assets. The company's operating cash flow is positive at 318,338,520 KRW, but this is insufficient to cover its free cash flow deficit. The company's future growth will depend on its ability to improve profitability and manage its debt burden.
The company faces several risk factors, including a high debt-to-equity ratio and a negative free cash flow, which could lead to liquidity constraints. The company's dilution potential is assessed as low, but its negative net cash position after subtracting total debt is a key flag. The company's risk assessment indicates that it is not currently facing significant dilution pressure, but its financial position remains vulnerable.
Recent events, as disclosed in the company's financial statements, include a significant operating and net loss, which may have impacted investor sentiment. The company's price target from analysts is 64,000 KRW, with a mean recommendation of 1.00, indicating a strong buy rating. However, the company's financial performance and risk profile suggest that investors should exercise caution.
- The company has a high debt-to-equity ratio of 1.28, indicating a moderate reliance on debt financing.
- The company's profitability is weak, with a net loss of 31,341,350,200 KRW and an operating loss of 25,890,557,570 KRW.
- The company's revenue is concentrated in a single segment, increasing its exposure to local economic and regulatory risks.
- The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year.
- The company faces several risk factors, including a high debt-to-equity ratio and a negative free cash flow, which could lead to liquidity constraints.
- **margin_outlook_rationale**: The company's gross profit margin is 57.4%, but this is insufficient to offset the operating and net losses, indicating a negative margin outlook.
- **rd_outlook_rationale**: The company's capital expenditures are negative, suggesting a reduction in investment in long-term assets, which may impact future research and development efforts.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 827,95 |
| Revenue | —no estimate | —no estimate | 137,2B KRW |
| Operating income | —no estimate | —no estimate | 15,1B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 042520.KQ Market data — financials · 2026-05-26
- Hans Biomed Corp Market data — analyst estimates · 2026-05-26